Redefining outcomes in asthma—remission and beyond The Lancet Respiratory Medicine + + +...

Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00239-5/abstract?dgcid=raven_jbs_etoc_feature_lanres Redefining outcomes in asthma—remission and beyond The Lancet Respiratory Medicine https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00367-4/fulltext?dgcid=raven_jbs_etoc_email Nov 2025 Volume 13Number 11p951-1040, e56-e58 https://www.thelancet.com/journals/lanres/issue/vol13no11/PIIS2213-2600(25)X0011-4